

Rational Design of Cyclic-Peptides for Inhibiting Cancer Proliferation

Yingjie Ling
Tufts University

Outline

Outline

- Background

Outline

- Background
- Project Description

Outline


- Background
- Project Description
- Results

Outline

- Background
- Project Description
- Results
- Conclusion and Next Steps

p27^{Kip1} and its significance

p27^{Kip1} is important for regulating cell cycles



R. Alicia, et al., *Nature* **382**, 425-331 (1996)

Background


Project Description

Results

Conclusion

p27^{Kip1} is important for regulating cell cycles


- p27^{Kip1} is a cyclin-dependent-kinase inhibitor that leads to cell-cycle arrest.



R. Alicia, et al., *Nature* **382**, 425-331 (1996)

p27^{Kip1} is important for regulating cell cycles


- p27^{Kip1} is a cyclin-dependent-kinase inhibitor that leads to cell-cycle arrest.
- p27^{Kip1} is often referred to as the “tumor suppressor”.



R. Alicia, et al., *Nature* **382**, 425-331 (1996)

p27^{Kip1} is important for regulating cell cycles

- p27^{Kip1} is a cyclin-dependent-kinase inhibitor that leads to cell-cycle arrest.
- p27^{Kip1} is often referred to as the “tumor suppressor”.
- In cancer cells, p27^{Kip1} is frequently inactivated.



R. Alicia, et al., *Nature* **382**, 425-331 (1996)

Background


Project Description

Results

Conclusion


p27^{Kip1} is important for regulating cell cycles

- p27^{Kip1} is a cyclin-dependent-kinase inhibitor that leads to cell-cycle arrest.
- p27^{Kip1} is often referred to as the “tumor suppressor”.
- In cancer cells, p27^{Kip1} is frequently inactivated.



R. Alicia, et al., *Nature* **382**, 425-331 (1996)

p27^{Kip1} is degraded by a ubiquitin-dependent process



Cks1: Cyclin-dependent kinases regulatory subunit 1

Skp2: S-phase kinase-associated protein 2


A. C. Carrano, et al., *Nat. Cell Biol.* **1**, 193-199 (1999)

D. Frescas & M. Pagano, *Nat. Rev. Cancer* **8**, 438-449 (2008)

J. Slingerland & M. Pagano, *J. Cell. Physiol.* **183**, 10-17 (2000)

p27^{Kip1} is degraded by a ubiquitin-dependent process

- Both Cks1 and Skp2 are required for the most efficient ubiquitylation of p27^{Kip1}.



Cks1: Cyclin-dependent kinases regulatory subunit 1

Skp2: S-phase kinase-associated protein 2


A. C. Carrano, et al., *Nat. Cell Biol.* **1**, 193-199 (1999)

D. Frescas & M. Pagano, *Nat. Rev. Cancer* **8**, 438-449 (2008)

J. Slingerland & M. Pagano, *J. Cell. Physiol.* **183**, 10-17 (2000)

p27^{Kip1} is degraded by a ubiquitin-dependent process

- Both Cks1 and Skp2 are required for the most efficient ubiquitylation of p27^{Kip1}.
- It was also shown that Cks1 and Skp2 are often over-expressed in cancer cells.



Cks1: Cyclin-dependent kinases regulatory subunit 1

Skp2: S-phase kinase-associated protein 2

A. C. Carrano, et al., *Nat. Cell Biol.* **1**, 193-199 (1999)

D. Frescas & M. Pagano, *Nat. Rev. Cancer* **8**, 438-449 (2008)

J. Slingerland & M. Pagano, *J. Cell. Physiol.* **183**, 10-17 (2000)

Inhibiting p27^{Kip1} ubiquitylation has beneficial effects

D. O. Morgan, *Nature* **374**, 131-134 (1995)

Y. Masui & C. L. Markert, *J. Exp. Zool.* **177**, 129-145 (1971)

M. Malumbres & M. Barbacid, *Nat. Rev. Cancer* **9**, 153-166 (2009)

Background

Project Description

Results

Conclusion

Inhibiting p27^{Kip1} ubiquitylation has beneficial effects

Cyclin

CDK

D. O. Morgan, *Nature* **374**, 131-134 (1995)

Y. Masui & C. L. Markert, *J. Exp. Zool.* **177**, 129-145 (1971)

M. Malumbres & M. Barbacid, *Nat. Rev. Cancer* **9**, 153-166 (2009)


Background

Project Description

Results


Conclusion

Inhibiting p27^{Kip1} ubiquitylation has beneficial effects



D. O. Morgan, *Nature* **374**, 131-134 (1995)
Y. Masui & C. L. Markert, *J. Exp. Zool.* **177**, 129-145 (1971)
M. Malumbres & M. Barbacid, *Nat. Rev. Cancer* **9**, 153-166 (2009)

Inhibiting p27^{Kip1} ubiquitylation has beneficial effects




D. O. Morgan, *Nature* **374**, 131-134 (1995)

Y. Masui & C. L. Markert, *J. Exp. Zool.* **177**, 129-145 (1971)

M. Malumbres & M. Barbacid, *Nat. Rev. Cancer* **9**, 153-166 (2009)

Inhibiting p27^{Kip1} ubiquitylation has beneficial effects




D. O. Morgan, *Nature* **374**, 131-134 (1995)

Y. Masui & C. L. Markert, *J. Exp. Zool.* **177**, 129-145 (1971)

M. Malumbres & M. Barbacid, *Nat. Rev. Cancer* **9**, 153-166 (2009)

Inhibiting p27^{Kip1} ubiquitylation has beneficial effects




D. O. Morgan, *Nature* **374**, 131-134 (1995)

Y. Masui & C. L. Markert, *J. Exp. Zool.* **177**, 129-145 (1971)

M. Malumbres & M. Barbacid, *Nat. Rev. Cancer* **9**, 153-166 (2009)

Inhibiting p27^{Kip1} ubiquitylation has beneficial effects




D. O. Morgan, *Nature* **374**, 131-134 (1995)

Y. Masui & C. L. Markert, *J. Exp. Zool.* **177**, 129-145 (1971)

M. Malumbres & M. Barbacid, *Nat. Rev. Cancer* **9**, 153-166 (2009)

Inhibiting p27^{Kip1} ubiquitylation has beneficial effects




D. O. Morgan, *Nature* **374**, 131-134 (1995)

Y. Masui & C. L. Markert, *J. Exp. Zool.* **177**, 129-145 (1971)

M. Malumbres & M. Barbacid, *Nat. Rev. Cancer* **9**, 153-166 (2009)

Inhibiting p27^{Kip1} ubiquitylation has beneficial effects



Unchecked Cell Proliferation


Background

Project Description


Results

Conclusion

Inhibiting p27^{Kip1} ubiquitylation has beneficial effects



Inhibiting p27^{Kip1} ubiquitylation has beneficial effects



Small molecules are insufficient to inhibit Cks1–Skp2

Background

Project Description

Results

Conclusion

Jones S, Thornton JM, *Proc. Natl. Acad. Sci. U.S.A.* **93**, 13-20 (1996)

Ungermannova, D. et al., *J. Biomol. Screen.* **18**, 910–920 (2013)

Small molecules are insufficient to inhibit Cks1–Skp2

- Past attempts to inhibit Cks1–Skp2 interaction with small molecules yielded unsatisfying results.

Jones S, Thornton JM, *Proc. Natl. Acad. Sci. U.S.A.* **93**, 13-20 (1996)

Ungermannova, D. et al., *J. Biomol. Screen.* **18**, 910–920 (2013)

Background


Project Description

Results

Conclusion

Small molecules are insufficient to inhibit Cks1–Skp2

- Past attempts to inhibit Cks1–Skp2 interaction with small molecules yielded unsatisfying results.




Jones S, Thornton JM, *Proc. Natl. Acad. Sci. U.S.A.* **93**, 13-20 (1996)

Ungermannova, D. et al., *J. Biomol. Screen.* **18**, 910–920 (2013)

Small molecules are insufficient to inhibit Cks1–Skp2

- Past attempts to inhibit Cks1–Skp2 interaction with small molecules yielded unsatisfying results.
- Protein–protein interactions are challenging to target using small molecules due to large and flat interfaces.




Jones S, Thornton JM, *Proc. Natl. Acad. Sci. U.S.A.* **93**, 13-20 (1996)

Ungermannova, D. et al., *J. Biomol. Screen.* **18**, 910–920 (2013)

Cyclic peptides bind protein surfaces with high affinity

PDB: 5AH4



A. Kling et al., *Science* **348**, 1106-1112 (2015)

Background

Project Description


Results

Conclusion

Cyclic peptides bind protein surfaces with high affinity

PDB: 5AH4

- Cyclic peptides have large surface area and can easily mimic functional groups at protein interfaces.



A. Kling et al., *Science* **348**, 1106-1112 (2015)

Background

Project Description


Results

Conclusion

Cyclic peptides bind protein surfaces with high affinity

PDB: 5AH4

- Cyclic peptides have large surface area and can easily mimic functional groups at protein interfaces.
- Without exposed terminal, cyclic peptides are also more stable, rendering high oral availability.



A. Kling et al., *Science* **348**, 1106-1112 (2015)

Background

Project Description

Results

Conclusion

Cyclic-peptide design is a 3-step process


Background

Project Description

Results

Conclusion

Cyclic-peptide design is a 3-step process



1. Identify a region important for binding

Background

Project Description

Results

Conclusion


Cyclic-peptide design is a 3-step process



1. Identify a region important for binding

2. Search for the best linker size

Cyclic-peptide design is a 3-step process




1. Identify a region important for binding

2. Search for the best linker size

3. Find linker sequence

Cyclic-peptide design is a 3-step process




1. Identify a region important for binding

2. Search for the best linker size

3. Find linker sequence

3⁹SESE4² is important for Cks1–Skp2 interaction



J. Gavenois et al., *Nat. Chem. Biol.* **10**, 716–722 (2014)

T. Siegert et al., *Methods Mol. Biol.* **1561**, 255-277 (2017)

B. Hal et al., *Mol. Cell* **20**, 9-19 (2005)


Background

Project Description

Results

Conclusion

3⁹SESE4² is important for Cks1–Skp2 interaction



J. Gavenois et al., *Nat. Chem. Biol.* **10**, 716–722 (2014)

T. Siegert et al., *Methods Mol. Biol.* **1561**, 255-277 (2017)

B. Hal et al., *Mol. Cell* **20**, 9-19 (2005)


Background

Project Description

Results

Conclusion

3⁹SESE⁴² is important for Cks1–Skp2 interaction



Yellow: residues contributing > 1 kcal/mol binding energy

Orange: residues contributing > 2 kcal/mol binding energy

J. Gavenois et al., *Nat. Chem. Biol.* **10**, 716–722 (2014)

T. Siegert et al., *Methods Mol. Biol.* **1561**, 255-277 (2017)

B. Hal et al., *Mol. Cell* **20**, 9-19 (2005)


Background

Project Description

Results

Conclusion

Cyclic-peptide design is a 3-step process




1. Identify a region important for binding

2. Search for the best linker size

3. Find linker sequence

Cyclic-peptide design is a 3-step process




1. Identify a region important for binding

2. Search for the best linker size


3. Find linker sequence

Create model systems and conduct simulations


cyclo-SESEG1




cyclo-SESEG2




cyclo-SESEG3




cyclo-SESEG4



cyclo-SESEG5



cyclo-SESEG6



Simulation results are analyzed in two ways

Background

Project Description

Results

Conclusion

Simulation results are analyzed in two ways

- Clash analysis:
 - Align each conformation to the binding pocket and check if the linker region has steric clashes with the binding target.


Simulation results are analyzed in two ways

- Clash analysis:
 - Align each conformation to the binding pocket and check if the linker region has steric clashes with the binding target.
- Cluster analysis:
 - Separate trajectory conformations into clusters to obtain the structural ensemble.


Clash Analysis

SESEG4 and SESEG5 best mimic the target conformation


cyclo-SESEG1




cyclo-SESEG2




cyclo-SESEG3




cyclo-SESEG4



cyclo-SESEG5



cyclo-SESEG6



Background


Project Description

Results

Conclusion

Clash analysis provides useful insights

cyclo-SESEG6



Background


Project Description

Results

Conclusion


Clash analysis provides useful insights

cyclo-SESEG6



Clash analysis provides useful insights

cyclo-SESEG6



Background


Project Description

Results


Conclusion

SESEG4 and SESEG5 best mimic the target conformation


cyclo-SESEG1




cyclo-SESEG2




cyclo-SESEG3




cyclo-SESEG4



cyclo-SESEG5



cyclo-SESEG6



Background


Project Description

Results



Conclusion

Cluster Analysis


SESEG4 and SESEG5 adopt target conformation with high population




Population: 7.5%
RMSD(Å): 0.244 ± 0.062



Population: 4.6%
RMSD(Å): 0.216 ± 0.059



Cyclic-peptide design is a 3-step process




1. Identify a region important for binding

2. Search for the best linker size

3. Find linker sequence

Cyclic-peptide design is a 3-step process




1. Identify a region important for binding


2. Search for the best linker size

3. Find linker sequence


SESEG4 and SESEG5 adopt target conformation with high population



Desired SESE conformation




Target cyclo-(SESEX₁X₂X₃X₄) structure



Target cyclo-(SESEX₁X₂X₃X₄X₅) structure

Linker sequence selection is informed by aa's intrinsic propensity




AA	P_{II}	β	α_R	α_L
P	0.80	0.00	0.15	0.00
A	0.46	0.23	0.21	0.02
L	0.43	0.21	0.26	0.02
M	0.40	0.24	0.21	0.03
E	0.40	0.22	0.28	0.03
I	0.39	0.36	0.20	0.00
W	0.39	0.26	0.23	0.03
C	0.38	0.31	0.18	0.03
V	0.37	0.39	0.19	0.00
F	0.35	0.33	0.20	0.03
Q	0.35	0.26	0.26	0.04
Y	0.34	0.32	0.21	0.03
R	0.34	0.27	0.26	0.04
K	0.34	0.26	0.29	0.04
S	0.33	0.25	0.33	0.02
H	0.30	0.30	0.22	0.06
T	0.29	0.28	0.38	0.00
D	0.29	0.09	0.43	0.05
N	0.24	0.15	0.30	0.13
G	0.21	0.09	0.09	0.27

Zhou, C.-Y., Jiang, F. & Wu, Y.-D. *J. Phys. Chem. B.* **119**, 1035-1047 (2015)

Linker sequence selection is informed by aa's intrinsic propensity

ϕ/ψ distribution of G₇ from cyclo-(SESEG4)





AA	P _{II}	β	α_R	α_L
D	0.29	0.09	0.43	0.05
T	0.29	0.28	0.38	0.00
S	0.33	0.25	0.33	0.02
N	0.24	0.15	0.30	0.13
K	0.34	0.26	0.29	0.04
E	0.40	0.22	0.28	0.03
L	0.43	0.21	0.26	0.02
Q	0.35	0.26	0.26	0.04
R	0.34	0.27	0.26	0.04
W	0.39	0.26	0.23	0.03
H	0.30	0.30	0.22	0.06
A	0.46	0.23	0.21	0.02
M	0.40	0.24	0.21	0.03
Y	0.34	0.32	0.21	0.03
I	0.39	0.36	0.20	0.00
F	0.35	0.33	0.20	0.03
V	0.37	0.39	0.19	0.00
C	0.38	0.31	0.18	0.03
P	0.80	0.00	0.15	0.00
G	0.21	0.09	0.09	0.27

Conformer Probability

AA	P_{II}	β	α_R	α_L
P	0.80	0.00	0.15	0.00
A	0.46	0.23	0.21	0.02
L	0.43	0.21	0.26	0.02
M	0.40	0.24	0.21	0.03
E	0.40	0.22	0.28	0.03
I	0.39	0.36	0.20	0.00
W	0.39	0.26	0.23	0.03
C	0.38	0.31	0.18	0.03
V	0.37	0.39	0.19	0.00
F	0.35	0.33	0.20	0.03
Q	0.35	0.26	0.26	0.04
Y	0.34	0.32	0.21	0.03
R	0.34	0.27	0.26	0.04
K	0.34	0.26	0.29	0.04
S	0.33	0.25	0.33	0.02
H	0.30	0.30	0.22	0.06
T	0.29	0.28	0.38	0.00
D	0.29	0.09	0.43	0.05
N	0.24	0.15	0.30	0.13
G	0.21	0.09	0.09	0.27

Linker sequence selection is informed by aa's intrinsic propensity




Conformer Probability

AA	P_{II}	β	α_R	α_L
P	0.80	0.00	0.15	0.00
A	0.46	0.23	0.21	0.02
L	0.43	0.21	0.26	0.02
M	0.40	0.24	0.21	0.03
E	0.40	0.22	0.28	0.03
I	0.39	0.36	0.20	0.00
W	0.39	0.26	0.23	0.03
C	0.38	0.31	0.18	0.03
V	0.37	0.39	0.19	0.00
F	0.35	0.33	0.20	0.03
Q	0.35	0.26	0.26	0.04
Y	0.34	0.32	0.21	0.03
R	0.34	0.27	0.26	0.04
K	0.34	0.26	0.29	0.04
S	0.33	0.25	0.33	0.02
H	0.30	0.30	0.22	0.06
T	0.29	0.28	0.38	0.00
D	0.29	0.09	0.43	0.05
N	0.24	0.15	0.30	0.13
G	0.21	0.09	0.09	0.27

Linker sequence selection is informed by aa's intrinsic propensity

ϕ/ψ distribution of G₅ from cyclo-(SESEG4)




Conformer Probability (PII)

AA	P_{II}	β	α_R	α_L
P	0.80	0.00	0.15	0.00
A	0.46	0.23	0.21	0.02
L	0.43	0.21	0.26	0.02
M	0.40	0.24	0.21	0.03
E	0.40	0.22	0.28	0.03
I	0.39	0.36	0.20	0.00
W	0.39	0.26	0.23	0.03
C	0.38	0.31	0.18	0.03
V	0.37	0.39	0.19	0.00
F	0.35	0.33	0.20	0.03
Q	0.35	0.26	0.26	0.04
Y	0.34	0.32	0.21	0.03
R	0.34	0.27	0.26	0.04
K	0.34	0.26	0.29	0.04
S	0.33	0.25	0.33	0.02
H	0.30	0.30	0.22	0.06
T	0.29	0.28	0.38	0.00
D	0.29	0.09	0.43	0.05
N	0.24	0.15	0.30	0.13
G	0.21	0.09	0.09	0.27


Linker sequence selection is informed by aa's intrinsic propensity

ϕ/ψ distribution of G₅ from cyclo-(SESEG4)

Conformer definition of L-aa's



Conformer definition of D-aa's




Conformer Probability (β)

AA	P_{II}	β	α_R	α_L
V	0.37	0.39	0.19	0.00
I	0.39	0.36	0.20	0.00
F	0.35	0.33	0.20	0.03
Y	0.34	0.32	0.21	0.03
C	0.38	0.31	0.18	0.03
H	0.30	0.30	0.22	0.06
T	0.29	0.28	0.38	0.00
R	0.34	0.27	0.26	0.04
W	0.39	0.26	0.23	0.03
Q	0.35	0.26	0.26	0.04
K	0.34	0.26	0.29	0.04
S	0.33	0.25	0.33	0.02
M	0.40	0.24	0.21	0.03
A	0.46	0.23	0.21	0.02
E	0.40	0.22	0.28	0.03
L	0.43	0.21	0.26	0.02
N	0.24	0.15	0.30	0.13
D	0.29	0.09	0.43	0.05
G	0.21	0.09	0.09	0.27
P	0.80	0.00	0.15	0.00


Linker sequence selection is informed by aa's intrinsic propensity

ϕ/ψ distribution of G₅ from cyclo-(SESEG4)

Conformer definition of L-aa's



Conformer definition of D-aa's





Conformer Probability (PII)

AA	P_{II}	β	α_R	α_L
P	0.80	0.00	0.15	0.00
A	0.46	0.23	0.21	0.02
L	0.43	0.21	0.26	0.02
M	0.40	0.24	0.21	0.03
E	0.40	0.22	0.28	0.03
I	0.39	0.36	0.20	0.00
W	0.39	0.26	0.23	0.03
C	0.38	0.31	0.18	0.03
V	0.37	0.39	0.19	0.00
F	0.35	0.33	0.20	0.03
Q	0.35	0.26	0.26	0.04
Y	0.34	0.32	0.21	0.03
R	0.34	0.27	0.26	0.04
K	0.34	0.26	0.29	0.04
S	0.33	0.25	0.33	0.02
H	0.30	0.30	0.22	0.06
T	0.29	0.28	0.38	0.00
D	0.29	0.09	0.43	0.05
N	0.24	0.15	0.30	0.13
G	0.21	0.09	0.09	0.27

Linker sequence selection is informed by aa's intrinsic propensity

ϕ/ψ distribution of G₆ from cyclo-(SESEG4)





Conformer Probability (β)

AA	P_{II}	β	α_R	α_L
V	0.37	0.39	0.19	0.00
I	0.39	0.36	0.20	0.00
F	0.35	0.33	0.20	0.03
Y	0.34	0.32	0.21	0.03
C	0.38	0.31	0.18	0.03
H	0.30	0.30	0.22	0.06
T	0.29	0.28	0.38	0.00
R	0.34	0.27	0.26	0.04
W	0.39	0.26	0.23	0.03
Q	0.35	0.26	0.26	0.04
K	0.34	0.26	0.29	0.04
S	0.33	0.25	0.33	0.02
M	0.40	0.24	0.21	0.03
A	0.46	0.23	0.21	0.02
E	0.40	0.22	0.28	0.03
L	0.43	0.21	0.26	0.02
N	0.24	0.15	0.30	0.13
D	0.29	0.09	0.43	0.05
G	0.21	0.09	0.09	0.27
P	0.80	0.00	0.15	0.00


Linker sequence selection is informed by aa's intrinsic propensity

ϕ/ψ distribution of G₆ from cyclo-(SESEG4)




Linker sequence selection is informed by aa's intrinsic propensity

ϕ/ψ distribution of G₈ from cyclo-(SESEG4)



Linker sequence selection is informed by aa's intrinsic propensity

ϕ/ψ distribution of G₈ from cyclo-(SESEG4)



Linker sequence selection is informed by aa's intrinsic propensity

Background

Project Description

Results

Conclusion

Linker sequence selection is informed by aa's intrinsic propensity

- The same method was used to find linker sequences for cyclic nonamer.

Linker sequence selection is informed by aa's intrinsic propensity

- The same method was used to find linker sequences for cyclic nonamer.
- 52 sequences were proposed in total.

Linker sequence selection is informed by aa's intrinsic propensity

- The same method was used to find linker sequences for cyclic nonamer.
- 52 sequences were proposed in total.
- Molecular dynamics simulations were carried out.


Linker sequence selection is informed by aa's intrinsic propensity

- The same method was used to find linker sequences for cyclic nonamer.
- 52 sequences were proposed in total.
- Molecular dynamics simulations were carried out.
- The results were analyzed.


cyclo-(SESEG~~GGG~~G) as the starting point

cyclo-(SESEG~~GGG~~G)

all conformations



conformations without clash



Background

Project Description


Results

Conclusion


cyclo-(SESEG~~GGG~~G) as the starting point

cyclo-(SESEG~~GGG~~G)

all conformations




conformations without clash




cyclo-(SESEG~~GGG~~G) as the starting point

cyclo-(SESEG~~GGG~~G)

all conformations




conformations without clash




Cyclo-(SESEavTG) greatly stabilizes target conformation

cyclo-(SESEG_nGGG)

all structures




structures without clash




cyclo-(SESEavTG)

all structures



structures without clash



Background

Project Description


Results

Conclusion


Cyclo-(SESEavTG) greatly stabilizes target conformation

cyclo-(SESEG_nGGG)

all structures




structures without clash




cyclo-(SESEavTG)

all structures



structures without clash



Background

Project Description


Results

Conclusion


Cyclo-(SESEavTG) greatly stabilizes target conformation

cyclo-(SESEG_nGGG)

all structures




structures without clash




cyclo-(SESEavTG)

all structures



structures without clash



Background

Project Description


Results

Conclusion


Cyclo-(SESEavTG) greatly stabilizes target conformation

cyclo-(SESEG_nGGG)

all structures




structures without clash




$\sim 3\times$

all structures



cyclo-(SESEavTG)

structures without clash



Background

Project Description


Results

Conclusion


Cyclo-(SESEavTG) greatly stabilizes target conformation

cyclo-(SESEG_nGGG)

all structures




structures without clash




~3x

all structures



cyclo-(SESEavTG)

structures without clash




Background

Project Description


Results

Conclusion


cyclo-(SESEGCGG) as the starting point





Population: 7.5%
RMSD(Å): 0.244 ± 0.062




Cyclo-(SESEavTG) greatly stabilizes target conformation



Population: 7.5%
RMSD(Å): 0.244 ± 0.062



Population: 78.4%
RMSD(Å): 0.245 ± 0.056




Background

Project Description



Results

Conclusion


Cyclo-(SESEavTG) greatly stabilizes target conformation



Population: 7.5%
RMSD(Å): 0.244 ± 0.062



Population: 78.4%
RMSD(Å): 0.245 ± 0.056



↓ $>10x$


Background

Project Description

Results



Conclusion

Cyclo-(SESEavTG) greatly stabilizes target conformation




Population: 7.5%

RMSD(Å): 0.244 ± 0.062



Population: 78.4%

RMSD(Å): 0.245 ± 0.056



↓ >10x


Background

Project Description

Results

Conclusion

Intracellular delivery requires high membrane permeability



Background


Project Description

Results

Conclusion


Intracellular delivery requires high membrane permeability

- Cks1–Skp2 interaction takes place intracellularly.



Intracellular delivery requires high membrane permeability



- Cks1–Skp2 interaction takes place intracellularly.
- cyclo-(SESEavTG) might not be “greasy” enough.





Cyclo-(SESEGvvTG) was picked for higher hydrophobicity

- Intracellular inhibition requires high membrane permeability.
- cyclo-(SESEGvvTG) has the greatest hydrophobicity among the top performers.

cyclo-(SESEGvvTG)




cyclo-(SESEGvvTG)



Does experimental results support predictions?

NMR identifies dominant structure for cyclo-(SESEavTG)




Background

Project Description

Results

Conclusion

NMR identifies dominant structure for cyclo-(SESEavTG)




Background

Project Description

Results

Conclusion

NMR identifies dominant structure for cyclo-(SESEavTG)



Background

Project Description

Results

Conclusion

NMR confirms structural prediction for cyclo-(SESEavTG)

Background


Project Description

Results

Conclusion

NMR confirms structural prediction for cyclo-(SESEavTG)


- Structures are built using simulated annealing while applying the restraints obtained from NMR.



Predicted Structure

NMR confirms structural prediction for cyclo-(SESEavTG)


- Structures are built using simulated annealing while applying the restraints obtained from NMR.
- Predicted structures show structural similarity to the constructed ones.




Predicted Structure

NMR confirms structural prediction for cyclo-(SESEavTG)

Predicted Structure



Constructed Structure




Background

Project Description

Results

Conclusion

NMR reveals hydrogen bond network in cyclo-(SESEavTG)



Residue	Slope (ppb/°C)
Ser1	-8.3
Glu2	-5.8
Ser3	-3.5
Glu4	1.8
D-Ala5	-4.7
D-Val6	-9
Thr7	-9.5
Gly8	-2.7

*using -4.5 ppb/°C as cutoff

Baxter, N. J. & Williamson, M. P., *J. Biomol. NMR* **9**, 359-369, (1997)


Background

Project Description

Results

Conclusion

NMR reveals hydrogen bond network in cyclo-(SESEavTG)




Residue	Slope (ppb/°C)	H-bond*
Glu4	1.8	Yes
Gly8	-2.7	Yes
Ser3	-3.5	Yes
D-Ala5	-4.7	No
Glu2	-5.8	No
Ser1	-8.3	No
D-Val6	-9	No
Thr7	-9.5	No

*using -4.5 ppb/°C as cutoff

Baxter, N. J. & Williamson, M. P., *J. Biomol. NMR* **9**, 359-369, (1997)

Simulation prediction of hydrogen bond network aligns with experimental data



Residue	Slope (ppb/°C)	H-bond	Predicted H-bond*
Glu4	1.8	Yes	Yes
Gly8	-2.7	Yes	Yes
Ser3	-3.5	Yes	No
D-Ala5	-4.7	No	Yes
Glu2	-5.8	No	No
Ser1	-8.3	No	No
D-Val6	-9	No	No
Thr7	-9.5	No	No

*using 50% as the cutoff



Background

Project Description

Results

Conclusion

Simulation prediction of hydrogen bond network aligns with experimental data





Background

Project Description

Results

Conclusion

Simulation prediction of hydrogen bond network aligns with experimental data




Background

Project Description

Results

Conclusion

Simulation prediction of hydrogen bond network aligns with experimental data





Background

Project Description

Results

Conclusion

Simulation prediction of hydrogen bond network aligns with experimental data




Background

Project Description

Results

Conclusion

Simulation prediction of hydrogen bond network aligns with experimental data





Background

Project Description

Results

Conclusion

Simulation prediction of hydrogen bond network aligns with experimental data






Background

Project Description

Results

Conclusion






Background

Project Description

Results

Conclusion




Background

Project Description

Results

Conclusion






Background

Project Description

Results

Conclusion




Background

Project Description

Results

Conclusion






Background

Project Description

Results

Conclusion



Background


Project Description

Results


Conclusion

In-vivo experiments indicate low inhibitory efficacy

- U2OS and HeLa cells were treated with cyclo-(SESEavTG) at different concentrations.
- Little to no inhibitory effect was observed.




In-vivo experiments indicate low inhibitory efficacy



In-vivo experiments indicate low inhibitory efficacy

- The cyclic peptides were introduced to the HeLa cells using electroporation.



***In-vivo* experiments indicate low inhibitory efficacy**

- The cyclic peptides were introduced to the HeLa cells using electroporation.

Background


Project Description

Results

Conclusion


In-vivo experiments indicate low inhibitory efficacy

- The cyclic peptides were introduced to the HeLa cells using electroporation.



In-vivo experiments indicate low inhibitory efficacy

- The cyclic peptides were introduced to the HeLa cells using electroporation.
- Little to no inhibitory effect was observed.



Background

Project Description

Results

Conclusion

In-vitro experiment setup


Background

Project Description

Results

Conclusion

In-vitro experiment setup



HeLa cell


Background

Project Description

Results

Conclusion

In-vitro experiment setup




Background

Project Description

Results

Conclusion

In-vitro experiment setup




Background

Project Description

Results

Conclusion

In-vitro experiment setup




Background

Project Description

Results

Conclusion

In-vitro experiment setup




Background

Project Description

Results

Conclusion

In-vitro experiment setup




Background

Project Description


Results

Conclusion

In-vitro experiments indicate low inhibitory efficacy



Ji, P. et al., *J. Biol. Chem.* **281**, 24058-24069, (2006)




Background

Project Description

Results

Conclusion

In-vitro experiments indicate low inhibitory efficacy



Ji, P. et al., *J. Biol. Chem.* **281**, 24058-24069, (2006)


Background

Project Description


Results

Conclusion

In-vitro experiments indicate low inhibitory efficacy



Ji, P. et al., *J. Biol. Chem.* **281**, 24058-24069, (2006)



Background

Project Description


Results

Conclusion

What went wrong?


S1 and E4 side-chains are involved in intra-molecular interactions

- Oxygen on S1 side-chain interacts with amide hydrogen of S3.
- Oxygens on E4 side-chain interacts with amide hydrogen of S1.



S1 and E4 side-chains are involved in intra-molecular interactions

- Oxygen on S1 side-chain interacts with amide hydrogen of S3.
- Oxygens on E4 side-chain interacts with amide hydrogen of S1.



S1 and E4 side-chains are involved in intra-molecular interactions

- Oxygen on S1 side-chain interacts with amide hydrogen of S3.
- Oxygens on E4 side-chain interacts with amide hydrogen of S1.

Background


Project Description

Results

Conclusion



S1 and E4 side-chains are involved in intra-molecular interactions

- Oxygen on S1 side-chain interacts with amide hydrogen of S3.
- Oxygens on E4 side-chain interacts with amide hydrogen of S1.




S1 and E4 side-chains are involved in intra-molecular interactions

- Oxygen on S1 side-chain interacts with amide hydrogen of S3.
- Oxygens on E4 side-chain interacts with amide hydrogen of S1.



SESE is necessary, but is it sufficient?



J. Gavenois et al., *Nat. Chem. Biol.* **10**, 716–722 (2014)

T. Siegert et al., *Methods Mol. Biol.* **1561**, 255-277 (2017)

B. Hal et al., *Mol. Cell* **20**, 9-19 (2005)


Background

Project Description

Results

Conclusion

SESE is necessary, but is it sufficient?



J. Gavenois et al., *Nat. Chem. Biol.* **10**, 716–722 (2014)

T. Siegert et al., *Methods Mol. Biol.* **1561**, 255-277 (2017)

B. Hal et al., *Mol. Cell* **20**, 9-19 (2005)


Background

Project Description

Results

Conclusion

SESE is necessary, but is it sufficient?



J. Gavenois et al., *Nat. Chem. Biol.* **10**, 716–722 (2014)

T. Siegert et al., *Methods Mol. Biol.* **1561**, 255-277 (2017)

B. Hal et al., *Mol. Cell* **20**, 9-19 (2005)

Background


Project Description

Results


Conclusion

Does the *in-vitro* experiment tell the whole story?

- Skp2 was already pre-occupied with endogenous Cks1.
- Can the inhibitor properly function when Cks1 already binds to Skp2?




Conclusion and next steps




Conclusion and next steps

- Designed cyclic peptides that are predicted to be well structured.




Conclusion and next steps

- Designed cyclic peptides that are predicted to be well structured.
- Structural predictions of cyclo-(SESEavTG) align well with NMR data.




Conclusion and next steps

- Designed cyclic peptides that are predicted to be well structured.
- Structural predictions of cyclo-(SESEavTG) align well with NMR data.
- Cell-based studies show little inhibitory effect of cyclo-(SESEavTG) and cycle-(SESEGvvTG).



Conclusion and next steps

- Designed cyclic peptides that are predicted to be well structured.
- Structural predictions of cyclo-(SESEavTG) align well with NMR data.
- Cell-based studies show little inhibitory effect of cyclo-(SESEavTG) and cycle-(SESEGvvTG).
- Verify our inhibitor design and experimental methods.



Acknowledgements

- Dr. Yu-Shan Lin (PI)
- Dr. Jiayuan Miao
- Francini Fonseca
- Jovan Damjanovic
- Kevin Schult
- James Baleja @ Tufts SOM
- Bradley Pentelute @ MIT
- Michele Pagano @ NYU SOM



Tufts Research
Cluster